Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Viatris
Pharma
FDA expert panel spurns Lexicon's approval bid in type 1 diabetes
An FDA advisory committee voted 11-3 to reject Lexicon's Zynquista as an adjunct medication to insulin for those with type 1 diabetes.
Kevin Dunleavy
Nov 1, 2024 11:24am
Viatris lays out $25M to tackle marketing of Lexicon's Inpefa
Oct 17, 2024 10:17am
Novo settles with Mylan over potential Ozempic generic
Oct 7, 2024 9:18am
Novartis, Viatris now face litigation over use of HeLa cells
Aug 6, 2024 8:06am
Viatris, former president cleared in DOJ price-fixing probe
Jul 2, 2024 9:40am
Viatris, eyeing a return to growth, taps Moderna alum as CCO
Apr 15, 2024 10:29am
